insights_auto
Why is BIIB34 up 6.39%?
Dive Deeperchevron_right
BIIB34:BVMF
Biogen Inc BDR
R$244.80
arrow_upward
+6.39%(+14.70) 1D
Nov 18, 4:56:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Open
R$244.80
High
R$244.80
Low
R$244.80
Mkt. cap
37.16B
Avg. vol.
9.00
Volume
15.00
52-wk high
R$244.80
52-wk low
R$147.50
Shares outstanding
147.82M
No. of employees
8K
Open
R$244.80
High
R$244.80
Low
R$244.80
Mkt. cap
37.16B
Avg. vol.
9.00
Volume
15.00
52-wk high
R$244.80
52-wk low
R$147.50
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
5 hours ago
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Yahoo Finance
·
6 hours ago
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
Investing.com
·
8 hours ago
Needham reiterates Biogen stock rating on Alzheimer’s drug data
Yahoo Finance
·
22 hours ago
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com